Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

SITC 2021 | BASECAMP-1: a premier example of precision medicine

Julian Molina, MD, PhD, Mayo Clinic, Rochester, MN, discusses how the BASECAMP-1 trial (NCT04981119) is a leading example of precision medicine. The study aims to evaluate subjects with solid tumors with a high risk of relapse for incurable disease and who might benefit from future CAR T-cell therapy. In the future, CAR T-cells could be tailored based on the presence of human leukocyte antigen (HLA) loss. The BASECAMP-1 study focuses on HLA-A*02 loss, which is the most prevalent loss in the United States, but at some point, the loss of other HLA markers can be targeted as well. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.